Ascendis Pharma A/S - American Depositary Shares (ASND)
130.66
+3.36 (2.64%)
Ascendis Pharma is a biotechnology company focused on developing innovative medicines using its proprietary TransCon technology platform
The company aims to address unmet medical needs, particularly in the areas of endocrine diseases and rare disorders, by creating optimally dosed therapies that enhance the bioavailability and efficacy of existing therapies. Through its robust pipeline, Ascendis Pharma is committed to advancing new treatment options that improve patient outcomes and quality of life, leveraging its expertise in drug development and deep understanding of biological mechanisms.
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments.
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139 price target.
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow breakeven target. Analysts remain optimistic about Yorvipath's market potential despite challenges.
